0001127602-21-015352.txt : 20210504
0001127602-21-015352.hdr.sgml : 20210504
20210504191550
ACCESSION NUMBER: 0001127602-21-015352
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210430
FILED AS OF DATE: 20210504
DATE AS OF CHANGE: 20210504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham Jonathan P
CENTRAL INDEX KEY: 0001365306
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 21890506
MAIL ADDRESS:
STREET 1: 2099 PENNSYLVANIA AVENUE, NW
STREET 2: 12TH FLOOR
CITY: WASHINGTON
STATE: DC
ZIP: 20006
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-04-30
0000318154
AMGEN INC
AMGN
0001365306
Graham Jonathan P
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
1
EVP, Gen. Counsel & Secy.
Common Stock
2021-04-30
4
A
0
3797
0
A
47762
D
Common Stock
2021-05-01
4
F
0
581
239.64
D
47181
D
Common Stock
2021-05-03
4
F
0
548
239.64
D
46633
D
Nqso (Right to Buy)
239.64
2021-04-30
4
A
0
32971
0
A
2023-04-30
2031-04-30
Common Stock
32971
32971
D
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
These shares include the following RSUs granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock
on a one-to-one basis.
These shares include 712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
/s/ Jonathan P. Graham
2021-05-04